Results of Operations

Ligand Pharmaceuticals Incorporated reported its first quarter 2026 financial results, which included a 56% year-over-year increase in royalty revenue. The company also announced a definitive agreement to acquire XOMA Royalty Corporation for $39.00 per share in cash, plus a Contingent Value Right.